Golden Biotechnology Corporation

Equities

4132

TW0004132006

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-05-22 EDT			5-day change	1st Jan Change
25.1 ^TWD	-1.95%		-7.38%	-36.05%

04-29	Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01-18	Golden Biotechnology Corp. Unveils the Findings of Its Phase II Clinical Trial Investigating Antroquinonol	CI

Golden Biotechnology Corp. announced that it expects to receive TWD 380 million in funding

April 11, 2016

Golden Biotechnology Corp. (GTSM:4132) announced a private placement of 3,800 convertible corporate bonds at TWD 100,000 per bond for gross proceeds of TWD 380,000,000 on April 12, 2016. The bonds have interest rate of 1% per annum and shall mature in five years.

Latest news about Golden Biotechnology Corporation

Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Golden Biotechnology Corp. Unveils the Findings of Its Phase II Clinical Trial Investigating Antroquinonol	01-18	CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-13	CI
Golden Biotech Announces Positive Results with Longer Survival Compared with Standard Treatments from Interim Analysis of Phase 2 Trial for Antroquinonol as 1st Line Treatment for Stage 4 Metastatic Pancreatic Cancer	23-05-05	CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-11	CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-27	CI
Golden Biotechnology Corporation Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients	22-01-07	CI
Golden Biotechnology Corporation Receives Antroquinonol Oral Covid-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe Covid-19 Patients	21-09-16	CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-15	CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-30	CI
GoldenBiotech's New Drug Antroquinonol Trial Receives Positive Response from DMC Review and Licenses for 4 Countries	21-02-04	CI
Golden Biotechnology Corp. Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia	20-11-26	CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-11	CI
Golden Biotechnology Corp. Announces it's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA	20-07-01	CI
Golden Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-05	CI
Golden Biotechnology Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-06	CI
Golden Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-01	CI
Golden Biotechnology Corporation(GTSM:4132) added to S&P Global BMI Index	18-09-24	CI
Golden Biotechnology Corporation announced that it has received TWD 48 million in funding	18-06-24	CI
Golden Biotechnology Corporation announced a financing transaction	18-06-19	CI
Golden Biotechnology Corp. announced that it expects to receive TWD 18.9 million in funding	16-08-22	CI
Golden Biotechnology Corp. cancelled the transaction announced on December 22, 2015	16-04-11	CI
Golden Biotechnology Corp. announced that it expects to receive TWD 380 million in funding	16-04-11	CI
Golden Biotechnology Corp. announced that it has received TWD 32.6 million in funding.	16-03-17	CI

Chart Golden Biotechnology Corporation

Duration

Period

More charts

Company Profile

Golden Biotechnology Corp is a Taiwan-based company mainly engaged in the development of new anti-cancer drugs. The Company's main development projects are novel compounds of Antroquinonol for the treatment of non-small cell lung cancer, acute myeloid leukemia, pancreatic cancer, hyperlipidemia, hepatitis B, and Corona Virus Disease 2019 (Covid-19), which are broadly effective small molecule drugs with no systemic toxicity. The Company is also engaged in the manufacture and sales of health foods and dietary supplements. The main products include antrodia camphorata mycelium capsules and others. The Company sells products in the Taiwan market as well as in other areas of Asia.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GOLDEN BIOTECHNOLOGY CORPORATION	-36.05%	113M
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B

Bio Therapeutic Drugs